Navigation Links
Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2

Alteon Inc. announced today that it has dosed its first patient in a 60-patient Phase 2 clinical trial (Study 201) of ALT-2074, its lead glutathione peroxidase mimetic, in diabetic patients with a variant of haptoglobin that renders them at high risk for cardiovascular complications.

This dose escalating study is designed to evaluate ALT-2074's ability to lower inflammatory cardiovascular biomarkers in patients with an elevated risk for cardiovascular events.

It builds on positive data from previous cardiovascular animal studies. ALT- 2074's activity in prior clinical trials demonstrated its safety and ability to lower inflammatory markers in ulcerative colitis.

'The initiation of Study 201 is a key milestone in our program for the development of ALT-2074 as a treatment for diabetic patients with a high risk of cardiovascular events,'said Malcolm W. MacNab, M.D., Ph.D., Alteon's Vice President, Clinical Development.

'We are enthusiastic about the potential that ALT-2074 has demonstrated in our preclinical models and we are aggressively pursuing clinical development in this indication.'

Diabetes and Metabolic Syndrome, diseases linked to obesity and increased oxidative stress, are growing in epidemic proportions in the United States and many other developed countries.

The major complications associated with these diseases are cardiovascular in nature, and lead to such events as stroke, heart attack, kidney failure and death. Not all patients with diabetes, however, experience these complications.

Several multinational studies have demonstrated that the increased risk of cardiovascular disease attributed to diabetes is more aptly attributed to the development of diabetes 'on top of' a predisposing genetic factor called Haptoglobin 2-2 (Hp2-2), which is found in 40% of the human population.

The combination of diabetes and Hp2-2 increases the susceptibil ity of patients to a defect in their cholesterol metabolism, which may promote atherosclerosis, and to a weakness in their antioxidant defense, so essential to the human body when oxygen is less available (during a heart attack for example).

Targeting a potent antioxidant drug candidate like ALT-2074 to these high risk patients is an example of targeted therapy. By redefining diabetes, Alteon believes that it can advance an efficient clinical development program in which a more appropriately targeted therapy is given to a more susceptible patient population.




'"/>




Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
6. SARS-Free Taiwan to Mark End Phase of Global Fight
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. FDA approves Phase 0 trial which tests experimental drugs on humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: